Governance

ICN is led by a Steering Board consisting of representatives of all ten core members. The Steering Board is the responsible, decision-making body. The Steering Board also decides on memberships and services offered.
The chairperson of the Steering Board is elected for a period of two years. The current chairperson is Dr Henry Yau of the Clinical Trials Center, the University of Hong Kong.


Steering Board:

C. Michael Gibson (MD): President, Baim Institute for Clinical Research, Boston, USA

Prof Dr Ian Wilkinson: Director of the Cambridge Clinical Trial Unit, Cambridge University Hospitals NHS Foundation Trust, United Kingdom

Dr phil Britta Lang: Director of Clinical Trials Unit Freiburg, Albert-Ludwigs-University of Freiburg, Germany

Henry Yau, (MBA): Managing Director of Clinical Trials Centre, The Hong Kong University, China

Prof Dr Yagiz √úresin: Vice Director of the Center of Excellence for Clinical Research, Istanbul University, Turkey

Associate Prof Dr Tsutomu Nishimura: Clinical Research Center International Development Office, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Japan

Dr med Christiane Blankenstein: Director of M√ľnchner Studienzentrum, Hospital rechts der Isar, Technical University of Munich, Germany

Prof Dr Rongxing Gan: President and CEO of Shanghai Clinical Research Center, China

Damien Hong, Chief Operating Officer of Singapore Clinical Research Institute, Singapore

Dr med Regina Grossman, Head of Clinical Trials Center Zurich, University Hospital Zurich, Switzerland

Organization

The ICN operates as much as possible on a decentralized basis. A core team manages common operations and processes.

Currently, ICN represents network without a legal entity. However, the Steering Board, as the highest decision making body of the ICN, will pursue adherence to agreed strategies, principles and standards.
With the current informal legal status of ICN, there are no financial obligations of members to the ICN organization or its leadership. Payable services will be contracted and settled bilaterally between the providing and the consuming partners.

Chairperson

Henry Yau, Managing Director of the Clinical Trials Centre, The University of Hong Kong, Hong Kong, China

Vice Chairperson

Dr Christiane Blankenstein, Director of the Munich Study Center, Technical University of Munich, Germany

Operational Office

Dr Anja Eskat, Annina Bauer und Deborah Eberle: Clinical Trials Center Zurich, University Hospital Zurich, Switzerland

Please contact us via: info@icn-connect.org